$15M credit line from Lincoln Park Capital.
$7M from sale of tax credits.
$40M from AMDX I.P.O.
$15M from renewed funding for ESS from D.O.D.
$25M up-front cash payment for development partnership for MANF for R.P.
$35M up-front cash payment for partnership for Eltoprazine.
Access to approximately $140M over the next two years. Funding won't be a problem.